Focus Partners Wealth
GLUE icon

Focus Partners Wealth’s Monte Rosa Therapeutics GLUE Stock Holding History

Focus Partners Wealth’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$191K Sell
11,612
-2,164
-16% -$41.4K ﹤0.01% 2431
2025
Q4 		$216K Buy
13,776
+2,052
+18% +$27.7K ﹤0.01% 2414
2025
Q3 		$86.9K Sell
11,724
-1,065
-8% -$5.64K ﹤0.01% 2136
2025
Q2 		$57.7K Buy
12,789
+801
+7% +$3.57K ﹤0.01% 1969
2025
Q1 		$55.6K Buy
11,988
+866
+8% +$5.31K ﹤0.01% 1837
2024
Q4 		$77.2K Buy
+11,122
New +$83.5K ﹤0.01% 1808

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Focus Partners Wealth's GLUE Position: Q1 2026 in Review

Focus Partners Wealth reduced its Monte Rosa Therapeutics (GLUE) stake by 16% in Q1 2026, selling an estimated $41.4K and leaving 11,612 shares worth $191K. The position accounts for ﹤0.01% of the portfolio, ranked #2431.

Focus Partners Wealth first reported a position in GLUE in Q4 2024 and has held it in 6 quarters since. The position peaked at $216K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Focus Partners Wealth held 11,612 shares of Monte Rosa Therapeutics worth $191K as of Q1 2026.
  • Focus Partners Wealth sold 2,164 Monte Rosa Therapeutics shares in Q1 2026, an estimated $41.4K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2431 holding.
  • Focus Partners Wealth first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Focus Partners Wealth's Monte Rosa Therapeutics position peaked at $216K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.